Leerink analyst Michael Schmidt says bluebird bio (BLUE) shares were weak on Friday following the presentation of competitor data from Global Blood Therapeutics (GBT) and Acceleron (XLRN) in sickle-cell disease and beta-thalassemia, respectively, at the European Hematology Association's congress. However, the analyst believes that given the differences between the treatment approaches and the likely different effect size and target patient population, both products could co-exist with bluebird's LentiGlobin within the hemoglobinopathies market. Schmidt reiterates an Outperform rating and $67 price target on bluebird's shares.
Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER - Krispy... To see the rest of the story go to thefly.com. See Story Here